Literature DB >> 17193820

Gastrointestinal stromal tumors: pathology and prognosis at different sites.

Markku Miettinen1, Jerzy Lasota.   

Abstract

Gastrointestinal (GI) stromal tumors (GISTs) are the most common mesenchymal tumors specific to the GI tract, generally defined as KIT (CD117)-positive tumors with a characteristic set of histologic features. These tumors, derived from Cajal cells or their precursors, most commonly occur at the age >50 years in the stomach (60%), jejunum and ileum (30%), duodenum (4-5%), rectum (4%), colon and appendix (1-2%), and esophagus (<1%), and rarely as apparent primary extragastrointestinal tumors in the vicinity of stomach or intestines. Their overall incidence has been estimated as 10 to 20 per million, including incidental minimal tumors. GISTs are rare in children (<1%) and almost exclusively occur in stomach. They are common in patients with neurofibromatosis 1, who have a predisposition to (multiple) small intestinal GISTs. GISTs contain a spectrum from minute indolent tumors to sarcomas at all sites of occurrence. Their gross patterns are diverse, including nodular, cystic, and diverticular tumors. External involvement of pancreas and liver can simulate primary tumor in these organs. In general, gastric tumors have a more favorable prognosis than the intestinal ones with similar parameters. Gastric GISTs < or =10 cm and < or =5 mitoses per 50 HPFs have a low risk for metastasis, whereas those with >5 per 50 HPFs and >5 cm in diameter have a high risk for metastasis. In contrast, all intestinal GISTs >5 cm independent of mitotic rate have at least moderate risk for metastases, and all >5 mitoses per 50 HPFs have a high risk for metastases. Intestinal GISTs < or =5 cm with < or =5 mitoses per 50 HPFs have a low risk for metastases. Gastric GISTs can be divided into histologic subgroups including 4 spindle cell and 4 epithelioid variants. Intestinal GISTs are a histologically more homogeneous group and often contain distinctive extracellular collagen globules, skeinoid fibers. Immunohistochemical demonstration of KIT, CD34, or protein kinase theta positivity helps to properly identify these tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17193820     DOI: 10.1053/j.semdp.2006.09.001

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  541 in total

1.  Laparoscopic resection for gastrointestinal stromal tumors in esophagogastric junction (EGJ): how to protect the EGJ.

Authors:  Wenjun Xiong; Jiaming Zhu; Yansheng Zheng; Lijie Luo; Yaobin He; Hongming Li; Dechang Diao; Liaonan Zou; Jin Wan; Wei Wang
Journal:  Surg Endosc       Date:  2017-08-04       Impact factor: 4.584

2.  A novel germline SDHB mutation in a gastrointestinal stromal tumor patient without bona fide features of the Carney-Stratakis dyad.

Authors:  Ricardo Celestino; Jorge Lima; Alexandra Faustino; Valdemar Máximo; António Gouveia; João Vinagre; Paula Soares; José Manuel Lopes
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

Review 3.  Molecular basis and management of gastrointestinal stromal tumors.

Authors:  Ulas D Bayraktar; Soley Bayraktar; Caio M Rocha-Lima
Journal:  World J Gastroenterol       Date:  2010-06-14       Impact factor: 5.742

Review 4.  Endoscopic management of gastrointestinal stromal tumors.

Authors:  Vinay Chandrasekhara; Gregory G Ginsberg
Journal:  Curr Gastroenterol Rep       Date:  2011-12

Review 5.  Malignant Rectal Gastrointestinal Stromal Tumour: Case Report and Review of Literature.

Authors:  Ana Catarina Lagos; Inês Marques; Jorge Reis; Irene Martins; Beatriz Neves
Journal:  J Gastrointest Cancer       Date:  2012-09

6.  A Gastrointestinal Stromal Tumor Presenting as an Emergency: a Case Report.

Authors:  Konstantinos Bouliaris; Aikaterini Michopoulou; Konstantinos Spanos; Vassilios Simopoulos; Ioannis Bolanis; Stylianos Germanos
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 7.  Adjuvant therapy of gastrointestinal stromal tumors (GIST).

Authors:  Paolo G Casali; Elena Fumagalli; Alessandro Gronchi
Journal:  Curr Treat Options Oncol       Date:  2012-09

8.  Outcomes After Surgical Resection Differ by Primary Tumor Location for Metastatic Gastrointestinal Stromal Tumors (GISTs): a Propensity Score Matching Population Study.

Authors:  Apostolos Gaitanidis; Michail Alevizakos; Alexandra Tsaroucha; Michail Pitiakoudis
Journal:  J Gastrointest Cancer       Date:  2019-12

9.  A Novel Pathological Prognostic Score (PPS) to Identify "Very High-Risk" Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST).

Authors:  Xuechao Liu; Haibo Qiu; Zhiming Wu; Peng Zhang; Xingyu Feng; Tao Chen; Yong Li; Kaixiong Tao; Guoxin Li; Xiaowei Sun; Zhiwei Zhou
Journal:  J Gastrointest Surg       Date:  2018-07-20       Impact factor: 3.452

10.  Gastrointestinal stromal tumors in the imatinib era: 15 years' experience of a tertiary center.

Authors:  Armando Peixoto; Pedro Costa-Moreira; Marco Silva; Ana Luísa Santos; Susana Lopes; Filipe Vilas-Boas; Pedro Moutinho-Ribeiro; Guilherme Macedo
Journal:  J Gastrointest Oncol       Date:  2018-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.